vein


 

 

 

 

 

 

Company Overview:

Aperion Biologics, Inc. is a clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology. Aperion Biologics, Inc. developed and patented a technique to make animal-tissues usable for human applications without causing rejection. The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both “humanizes” and sterilizes the tissues without affecting their biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled. Aperion’s Z-Process® of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to valves and vessels to soft tissue grafts for augmentation and repair. The company’s lead product for knee ligament reconstruction, the Z-Lig® ACLR Device, is currently under clinical investigation and not commercially approved for sale in the United States, European Union or other markets.

ABI’s Highlights:

  • Non-human tissue implants that remodel over the long-term
  • 28 issued U.S. and Outside of U.S. (OUS) patents enable Aperion to stand alone in the graft industry
  • Patients and surgeons have no viable alternative to human–based grafts, especially in anterior cruciate ligament (ACL) reconstruction
  • Existing shortage of consistent quality human-based tissue grafts
  • Aperion’s ACL replacement, Z-Lig® is the only candidate in advanced clinical development and with long term pilot clinical data. 
  • Currently in clinical trials in Europe and South Africa.
  • Proprietary product platform has broad applicability to other graft types
  • Dynamic and functional tissue scaffolds optimize the delivery of bioactive agents such as cells and autologous or exogenous growth factors.

 

The Z-Lig® device has not been approved for sale in the United States, European Union or other markets.

 

 
©2009 Aperion Biologics Corporation. All rights reserved. Privacy policy. Access to and use of this Web site is subject to these Terms of Use.